GCAN Greater Cannabis Company Inc (PK)

GammaCan International Inc.(OTCBB:GCAN), a developer of immunotherapies for cancer and other diseases, today announced that the Company filed two Continuations in Part (CIP) with the U.S. Patent and Trademark Office. The first CIP is titled �Administration of Gamma Globulins to Treat Metastatic Melanoma� and builds on the pre-clinical work conducted at GammaCan and substantiates these findings with data from ongoing clinical trials. The second CIP is titled �Administration of Gamma Globulins to Treat Cancer� and provides experimental data supporting the use of IgG based therapy for colorectal cancers. �These patent filings further strengthen GammaCan�s intellectual property position for the use of IgG based therapies to treat cancers in general, and more specifically, of melanoma and colorectal cancers. Over the past six months we have made progress with our research and clinical programs � we now beginning to see the first fruits of these efforts,� commented Patrick Schnegelsberg CEO. On a Separate matter GammaCan also announced that the Company extended the enrollment period for its GCAN 01 phase II trial to enroll additional patients. About GCAN 01 GCAN 01 is an open label, 30 patient phase II trial designed to evaluate the efficacy and safety of IgG therapy in late stage cancer patients who failed all current therapies. The trial is enrolling patients with colon cancer, melanoma and prostate cancer. The colon and melanoma arms are fully enrolled. Data from the melanoma arm was presented at a conference in 2006 and a scientific paper is in press. About GammaCan International, Inc GammaCan is focusing on the commercialization of an innovative anti-cancer immunotherapy to treat metastatic cancer. GammaCan's platform is based on IgG, a safe, relatively non-toxic human plasma-based product, currently used to treat a variety of immune deficiencies and autoimmune diseases. IgG works by strengthening the patient's immune system. Many experts currently view immunotherapy as a future alternative to today's standard chemotherapy. GammaCan is developing VitiGam, its second generation program. VitiGam is an IgG derived from the plasma of vitiligo donors and is being developed to treat malignant melanoma. GammaCan owns, and has applied for US patent protection covering the use of IgG and vitiligo-derived IgG (VitiGam). For more information about GammaCan visit www.GammaCan.com or call the company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616 or toll free 1-866-308-0396 (from North America). Safe Harbor Statement: Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding: the commercialization of an anti-cancer immunotherapy and the Company developing the boosting of cancer patients' immune systems with IVIG into an effective treatment. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology, inability to hire appropriate staff to develop the technology, unforeseen technical difficulties in developing the technology, inability to obtain regulatory approval for human use, competitors' therapies proving more effective, cheaper or otherwise preferable for consumers, inability to market the product we produce, among other factors, all of which could among other things, delay or prevent product release or cause our company to fail. For further risk factors see the risk factors associated with other early stage medical research and development companies filed with the SEC on Edgar.